MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Charles River Laboratories International Inc

Gesloten

SectorGezondheidszorg

219.06 0.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

214.89

Max

227.8

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9M

56M

Verkoop

-27M

1B

EPS

2.43

Winstmarge

5.529

Werknemers

18,700

EBITDA

-23M

198M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-6.22% downside

Dividenden

By Dow Jones

Volgende Winsten

18 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

10B

Vorige openingsprijs

219

Vorige sluitingsprijs

219.06

Nieuwssentiment

By Acuity

50%

50%

173 / 370 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jan 2026, 23:54 UTC

Marktinformatie

CBA Could Underperform Again in 2026 -- Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

12 jan 2026, 23:43 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 jan 2026, 23:18 UTC

Acquisities, Fusies, Overnames

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 jan 2026, 21:56 UTC

Marktinformatie

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 jan 2026, 20:54 UTC

Winsten

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 jan 2026, 20:48 UTC

Marktinformatie

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 jan 2026, 20:33 UTC

Marktinformatie

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 jan 2026, 19:39 UTC

Marktinformatie

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 19:33 UTC

Marktinformatie

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 jan 2026, 19:24 UTC

Acquisities, Fusies, Overnames

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 jan 2026, 19:22 UTC

Acquisities, Fusies, Overnames

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 jan 2026, 18:21 UTC

Acquisities, Fusies, Overnames

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 jan 2026, 18:20 UTC

Acquisities, Fusies, Overnames

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 jan 2026, 18:19 UTC

Marktinformatie

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 jan 2026, 18:16 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 jan 2026, 18:01 UTC

Acquisities, Fusies, Overnames

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 jan 2026, 18:00 UTC

Marktinformatie

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Vergelijking

Prijswijziging

Charles River Laboratories International Inc Prognose

Koersdoel

By TipRanks

-6.22% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 202.1 USD  -6.22%

Hoogste 225 USD

Laagste 170 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Charles River Laboratories International Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

8

Buy

4

Hold

0

Sell

Technische score

By Trading Central

117.16 / 144.77Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

173 / 370 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat